Pharma RSS Digest - 2026-07-01

Overview

The window was dominated by company-specific catalysts rather than broad sector themes. A standout oncology readout from AbbVie and Genmab showed a bispecific antibody combination meaningfully outperforming chemotherapy in a hard-to-treat lymphoma, reinforcing momentum behind chemotherapy-free regimens in B-cell cancers. On the regulatory side, Health Canada became the first major regulator to clear a generic version of Wegovy for chronic weight management, while a U.S. structural heart player won the go-ahead to begin a pivotal trial of a transcatheter tricuspid valve replacement. The watchlist mixes a high-severity device recall, a sizable take-private, early-stage vaccine science, and a thinly capitalized biotech's quarterly results. Overall, the tape is light, but each of the lead items carries clear directional implications for the companies involved.

Key Developments

AbbVie and Genmab reported that their Phase 3 EPCORE DLBCL-4 trial met its primary endpoint, with epcoritamab plus lenalidomide cutting the risk of disease progression or death by roughly 60% versus R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma. The result positions the combination as a potential chemotherapy-free option for second-line R/R DLBCL, a setting where alternatives after CAR-T failure or transplant ineligibility remain limited, and could support a label expansion for the already-marketed EPKINLY/TEPKINLY franchise. Investors should watch for the full data presentation at a future medical meeting, overall survival readouts, and any disclosure of regulatory filing timelines, since none were provided in the topline release.

AbbVie Inc. clinical trial update

Apotex became the first company to receive Health Canada approval for a generic of Wegovy (semaglutide) for chronic weight management, with the product to be marketed as SEVMIA in a multi-use pre-filled pen. The approval is the company's second semaglutide nod, following Apo-Semaglutide Injection, and positions Apotex as an early mover in Canada's generic GLP-1 obesity market — a development that could pressure pricing of Novo Nordisk's Wegovy and broaden treatment access. Key unknowns include the launch date, pricing, and any IP or litigation risk with the reference product's sponsor, none of which were addressed in the announcement.

Apotex first to fda approval update

Laplace Interventional secured FDA Investigational Device Exemption approval for its TRIUMPH pivotal trial of a transcatheter tricuspid valve replacement system, enabling enrollment of roughly 400 patients across up to 75 U.S. sites with a 2:1 randomization against commercial TTVR and a 150-patient registry arm. The trial is a critical step toward potential premarket authorization in a structural heart segment where device options remain limited relative to aortic and mitral markets, and the company's addressable U.S. population estimate exceeds 1.6 million patients. Watch for disclosure of primary endpoints, follow-up duration, comparator specifics, and any eventual PMA submission timeline, all of which were left unspecified in the announcement.

Laplace fda approval update

Watchlist

• Hologic is recalling all BioZorb and BioZorb LP 3D bioabsorbable markers after 252 reported injuries, in what the FDA classified as its most serious recall type; the company has issued updated clinician guidance for patients with existing implants. [link]
• Select Medical Holdings was taken private by a consortium including co-founders and WCAS in a roughly $3.9 billion deal at $16.50 per share, removing a major post-acute and rehabilitation provider from public markets effective July 1, 2026. [link]
• Early clinical data on the SchistoShield schistosomiasis vaccine, published in npj Vaccines, showed robust B- and T-cell memory responses across U.S. and African trial participants, with the program targeting a disease burden of roughly 250 million infections and 290,000 deaths annually. [link]
• Devonian Health Group reported a narrowed quarterly loss but saw cash fall to C$0.7M from C$7M nine months earlier, underscoring a near-term funding need as the company narrows its focus to Thykamine in radiodermatitis, pediatric atopic dermatitis, and MASH. [link]